Arcutis Biotherapeutics, Inc. ARQT Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s operating lease liabilities?
- Arcutis Biotherapeutics, Inc. (ARQT) reported operating lease liabilities of $5.25M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s operating lease liabilities changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s operating lease liabilities increased by 124.4% year-over-year, from $2.34M to $5.25M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s operating lease liabilities?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s operating lease liabilities has grown at a 1.2% compound annual growth rate (CAGR), from $4.96M to $5.27M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.